Platelets from patients with diabetes are hyperreactive and demonstrate increased adhesiveness, aggregation, degranulation, and thrombus formation, processes that contribute to the accelerated development of vascular disease. Part of the problem seems to be dysregulated platelet Ca 2؉ signaling and the activation of calpains, which are Ca 2؉ -activated proteases that result in the limited proteolysis of substrate proteins and subsequent alterations in signaling. In the present study, we report that the activation of -and m-calpain in patients with type 2 diabetes has profound effects on the platelet proteome and have identified septin-5 and the integrin-linked kinase (ILK) as novel calpain substrates. The calpain-dependent cleavage of septin-5 disturbed its association with syntaxin-4 and promoted the secretion of ␣-granule contents, including TGF-␤ and CCL5. Calpain was also released by platelets and cleaved CCL5 to generate a variant with enhanced activity. Calpain activation also disrupted the ILK-PINCH-Parvin complex and altered platelet adhesion and spreading. In diabetic mice, calpain inhibition reversed the effects of diabetes on platelet protein cleavage, decreased circulating CCL5 levels, reduced plateletleukocyte aggregate formation, and improved platelet function. 
Introduction
Calpains are Ca 2ϩ -regulated cysteine proteases that are responsible for the limited proteolysis of target proteins, resulting in their modification (eg, activation, inhibition, or altered sensitivity to intracellular signals) rather than in their degradation. 1 In contrast to promiscuous degradative proteases, calpains cleave a relatively restricted set of protein substrates and use complex substrate recognition mechanisms involving primary and secondary structural features of target proteins to alter protein function and cellular signaling. 2 Platelets express -calpain (calpain 1) and m-calpain (calpain 2); named for the micro-and millimolar Ca 2ϩ concentrations, respectively, that are required to activate them in vitro. 3 Although Ca 2ϩ is the main regulator of calpain activity, protease activation does not simply occur in response to any stimuli that increases platelet Ca 2ϩ . Indeed, the regulation of proteolytic activity is complex and involves the association of calpain with a regulatory subunit, the endogenous inhibitor calpastatin, 4 other interacting proteins, 5 and binding to phospholipids. 6, 7 Genetic deletion of m-calpain results in embryonic lethality, 8, 9 but -calpain Ϫ/Ϫ mice are viable and demonstrate attenuated aggregation and clot retraction but normal bleeding times. 10 Mechanistically, the latter effects were attributed to the tyrosine dephosphorylation of platelet proteins because -calpain Ϫ/Ϫ platelets exhibited high levels of tyrosine phosphatase 1B protein and activity. Moreover, either an inhibitor of the phosphatase or the generation of -calpaintyrosine phosphatase 1B double-knockout mice has been shown to rescue the platelet defect. 11 However, it is almost certain that the cleavage of a single phosphatase cannot account for the consequences of -calpain activation in platelets.
Pathophysiologically, the oxidative stress associated with type 2 diabetes results in the inactivation of the sarcoplasmic endoplasmic reticulum Ca 2ϩ ATPase (SERCA-2) and a subsequent increase in platelet Ca 2ϩ levels that is sufficient to activate calpain. This leads to the limited proteolysis of target proteins without eliciting full-blown platelet activation. 12 Several platelet proteins are known to be calpain substrates, including spectrin, adducin, talin, CD31, the myosin light-chain kinase, and N-ethylmaleimide-sensitivefactor attachment receptor (SNARE) proteins such as SNAP-23 and vesicle-associated membrane protein 3 (VAMP-3). 13 However, the spectrum of proteins that serve as pathophysiologically relevant targets of calpain in diabetic humans and their eventual role in the accelerated development of cardiovascular disease is unknown. Given that it is currently not possible to identify calpain targets on the basis of a specific recognition sequence, in the present study, we used a proteomic approach to identify novel calpain targets in diabetic platelets and to elucidate their role in platelet function. To determine which platelet proteins could be affected by calpain activation/inhibition in diabetic humans, we made use of the fact that peroxisome proliferator-activated receptor (PPAR)␥ agonist therapy increases SERCA-2 expression, normalizes platelet Ca 2ϩ , attenuates calpain activation, and prevents substrate cleavage. 12
Methods
For full details of all methods, please see supplemental Methods (available on the Blood Web site; see the Supplemental Materials link at the top of the online article).
Pioglitazone study population
A total of 13 patients with type 2 diabetes mellitus were used in this study (5 women and 8 men; mean age, 47 Ϯ 5.4 years; age range, 30-70 years; see supplemental Tables 1 and 2 for patient characteristics and medications). Patients were treated with either pioglitazone 30 mg/d (Actos; Takeda) or placebo each for 12 weeks in a cross-sectional design. There was a 4-week washout period between the different treatments. The study protocol was approved by the ethics committee of the Technical University of Dresden (number EK 233112006), and all of the participants gave written informed consent in accordance with the Declaration of Helsinki. Nondiabetic, age-matched subjects (7 women and 8 men; mean age, 40.25 Ϯ 6.5 years; age range, 23-50 years; glycated hemoglobin (HbA 1c ), 5.2% Ϯ 0.6%; fasting plasma glucose, 5.1 Ϯ 0.2mM) who had not taken any medication known to interfere with platelet aggregation for at least 10 days before the experiment served as the control group.
Diabetic study population
A total of 30 patients (16 women and 14 men; mean age, 47 Ϯ 5.4 years; age range, 30-70 years) with type 2 diabetes mellitus attending the clinic for routine control visits were included in the study. Patients had to have HbA 1c more than 7.4% and fasting plasma glucose of 8.2 Ϯ 0.7mM. All patients were treated with insulin alone or in combination with metformin. Nondiabetic, age-matched subjects (12 women and 18 men; mean age, 42.4 Ϯ 4.5 years; age range, 25-65 years; HbA 1c , 5.2% Ϯ 0.6%; fasting plasma glucose, 5.1 Ϯ 0.2mM) who had not taken any medication known to interfere with platelet aggregation for at least 10 days before the experiment served as the control group. The study protocol was approved by the ethics committee of the Goethe University Hospital (number E 61/09 geschäfts number 86/09) and all of the participants gave written informed consent in accordance with the Declaration of Helsinki.
Animals
C57BL/6 mice (6-8 weeks of age) were from Charles River Laboratories. Floxed -calpain Ϫ/Ϫ mice (-cal fl/fl ) were generated by Taconic Artemis and bred with animals expressing the Cre deleter under the control of the PF4 promoter (The Jackson Laboratory) to generate mice lacking -calpain in platelets (PF4--cal Ϫ/Ϫ ). Mice were housed in conditions that conform to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH publication no. 85-23). Both the university animal care committees and the Federal Authorities for Animal Research, Regierungspräsidium Darmstadt (Hessen, Germany; #F28/17) approved the study.
Diabetes was induced with a single IP injection of streptozotocin (150 mg/kg) and animals were considered diabetic when fasting plasma glucose was more than 250 mg/dL. In some experiments, animals were treated by oral gavage with the calpain inhibitor A-705253 (30 mg/kg/d) for 12 days after 12 weeks of untreated diabetes.
Statistical analysis
Data are expressed as means Ϯ SEM and statistical evaluation was performed using the Student t test for unpaired data or 1-way ANOVA followed by a Bonferroni t test where appropriate using Prism 5 software (GraphPad). P values Ͻ .05 were considered statistically significant.
Results

Proteomic analysis of platelets from patients with and without pioglitazone therapy
Platelets were obtained from diabetic subjects before and after 12 weeks of therapy with pioglitazone (30 mg/d). Pioglitazone therapy increased insulin sensitivity (supplemental Table 1 ) and had profound effects on the platelet proteome ( Figure 1A , supplemental Figure 1 , supplemental Table 3 ). More than half of the differentially expressed protein spots identified were known calpain substrates (eg, talin-1 and filamin A) 13 and could be classified as cytoskeletal proteins and signaling molecules involved in metabolism and vesicle/secretory trafficking. Some of the proteins identified (eg, septin-5, the integrin-linked kinase [ILK] and glycerol-3-phosphate dehydrogenase 2 (GPD2) have not been previously linked with calpain.
To differentiate between calpain substrates and PPAR␥-regulated genes, we determined the consequences of in vitro calpain activation on the levels of septin-5, ILK, and GPD2 in platelets from healthy subjects. Because platelet agonists alone are poor activators of the protease, calpains were activated via the Ca 2ϩ -sensing receptor by increasing the extracellular concentration of Ca 2ϩ as described previously 12 or using the combination of Ca 2ϩ and ionomycin. The 2 approaches were also used to differentiate between -and m-calpain activation, both of which are expressed in platelets. In human platelets, extracellular Ca 2ϩ was sufficient to stimulate the autolytic cleavage of -calpain and the limited degradation of septin-5 ( Figure 1B) . However, the combination of Ca 2ϩ and ionomycin was required to activate m-calpain (decrease in latent m-calpain levels), which in turn resulted in the further degradation of septin-5 and ILK ( Figure 1B ). Because all of these changes were sensitive to the calpain inhibitor calpeptin, they could be attributed to calpain activation. GPD2 was unaffected by calpain activation, an observation that fits well with its classification as a PPAR␥-regulated gene. 14 We also confirmed that levels of septin-5 and ILK were reduced in diabetic versus healthy subjects and increased as a result of pioglitazone therapy, which also reducedand m-calpain activation ( Figure 1C) . Because calpain inhibitors are not able to differentiate between -and m-calpain, we studied the sensitivity of septin-5 and ILK to Ca 2ϩ -induced, calpain-mediated cleavage in mice lacking -calpain in platelets (PF4--calpain Ϫ/Ϫ mice). The limited proteolysis of septin-5 was observed in Ca 2ϩ -stimulated platelets from -cal fl/fl mice, but not their PF4--cal Ϫ/Ϫ littermates ( Figure 1D arrow) . The combination of Ca 2ϩ and ionomycin resulted in the further degradation of septin-5 ( Figure 1D arrowhead) and was equally effective in -cal fl/fl and PF4--cal Ϫ/Ϫ mice. Conversely, the degradation of ILK was only observed in platelets treated with Ca 2ϩ and ionomycin, and was unaffected by the platelet-specific down-regulation of -calpain.
Calpain-dependent cleavage of septin-5 increases ␣-granule secretion
Septin-5 is a cytosolic GTP-binding protein that inhibits platelet degranulation by binding the SNARE protein syntaxin-4. 15 Septin-5 associated with syntaxin-4 in unstimulated platelets, but not after calpain activation with Ca 2ϩ or the combination of Ca 2ϩ and thrombin (Figure 2A) . Conversely, calpain inhibition enhanced the syntaxin-4/septin-5 association. To determine the consequences of this interaction on platelet degranulation, we assayed the release of the dense granule marker serotonin and the ␣-granule protein TGF-␤ in the absence and presence of Ca 2ϩ and thrombin. Serotonin release was stimulated by thrombin, but was not affected by calpain activation/inactivation ( Figure 2B ), whereas thrombin was able to stimulate TGF-␤ release only after Ca 2ϩ -induced calpain activation and not in the presence of the calpain inhibitor. Therefore, a calpain-sensitive process such as the cleavage of septin-5 seems to promote the release of ␣-granule contents actively.
CCL5 (RANTES) is a chemokine stored in ␣-granules that can be deposited onto the endothelium, where it attracts monocytes and can promote the development of vascular disease. 16 In contrast to TGF-␤, small amounts of CCL5 were released from thrombinstimulated platelets, but calpain activation increased CCL5 release significantly, whereas calpeptin inhibited it ( Figure 2C ). Moreover, circulating CCL5 was increased in plasma from diabetic subjects ( Figure 2D ), and more CCL5 was deposited by Ca 2ϩ -activated platelets onto endothelial cells ( Figure 2E ).
Cleavage of CCL5 by -calpain enhances chemotactic activity
Calpain activation in human platelets also resulted in CCL5 cleavage ( Figure 3A) . The latter phenomenon could be confirmed in vitro using the recombinant protein and resulted in the generation of a variant with enhanced monocyte chemotactic activity ( Figure 3B ). To identify the CCL5 variant generated by -calpain, CALPAIN ACTIVATION AND THE DIABETIC PLATELET PROTEOME 417 BLOOD, 12 JULY 2012 ⅐ VOLUME 120, NUMBER 2
For personal use only. at King's College London on July 30, 2012. bloodjournal.hematologylibrary.org From platelet-derived CCL5 and recombinant CCL5 protein were exposed to -calpain in vitro and then subjected to mass spectrometry. These experiments identified the peptide YSSDTTPCCFAY-IARPLPR (supplemental Figure 2) , representing residues 3-21, suggesting that -calpain cleaves CCL5 at the 2 first N-terminal amino acids and at a C-terminal position.
Calpain-mediated CCL5 cleavage may take place either in ␣-granules or in the extracellular space after its release. We found that -calpain was secreted from thrombin-stimulated platelets ( Figure 3C ), a finding that fits well with a recent report that identified calpain in the platelet secretome. 17 Indeed, calpain activity was measurable in plasma from healthy subjects and was Calpain activity in plasma from healthy subjects and from patients with type 2 diabetes. (E) CCL5 and -calpain in circulating microparticles isolated from healthy subjects (CTL) and patients with type 2 diabetes (Dia). The graphs summarize data obtained with 5-6 subjects per group. *P Ͻ .05; **P Ͻ .01; ***P Ͻ .001 versus CTL/Sol; #P Ͻ .05 versus full-length CCL5.
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-calpain activation disrupts the ILK-PINCH-Parvin complex and promotes ILK activation
The second novel calpain substrate we identified was ILK. ILK forms the so-called ILK-PINCH-Parvin (IPP) complex, which is part of the focal adhesion complex and functions as a regulator of several signaling pathways. 18 We found that PINCH and ␣-Parvin were coprecipitated with the ILK from unstimulated platelets, and the Ca 2ϩ -induced activation of -calpain resulted in the calpeptinsensitive disassociation of PINCH from the kinase ( Figure 4A ). To determine the consequences of calpain activation on ILK activity, we assessed the ability of PINCH-ILK complexes to phosphorylate the ILK substrate Akt. 19, 20 The ILK that coprecipitated with PINCH from untreated human platelets and added to unstimulated platelet lysates elicited a moderate phosphorylation of Akt. However, when the coprecipitate was treated with -calpain to disassociate ILK from PINCH, Akt phosphorylation increased. Conversely, incubation of the immunoprecipitates with m-calpain resulted in the degradation of ILK and failed to elicit Akt phosphorylation ( Figure  4B ). In vitro stimulation of washed human platelets with ionomycin to activate both calpain isoforms led to the cleavage of ILK and ␣-Parvin, but did not affect the level of PINCH significantly, suggesting that, in addition to ILK, ␣-Parvin is also an m-calpain substrate ( Figure 4C ). The cleavage of both proteins was prevented by calpeptin. Therefore, -calpain activation promotes the release of active ILK from the IPP complex, whereas the activation of m-calpain degrades 2 of the IPP proteins.
Differential contribution of -and m-calpain to platelet adhesion and spreading
The IPP complex assembles in the cytoplasm and is recruited subsequently to focal adhesions. 21 Therefore, we next focused on the role of calpain in regulating focal adhesion proteins and platelet adhesion and spreading. Indeed, 2 additional kinases linked to focal adhesion contacts, focal adhesion kinase (FAK) and proline-rich tyrosine kinase 2 (PYK2), were also attenuated in platelets from diabetic subjects ( Figure 5A ) and cleaved by calpain in vitro ( Figure 5B ). This is important because the proteolysis of focal adhesion proteins such as talin, paxillin (both are calpain substrates), and FAK is known to regulate focal adhesion dynamics and cell migration. 22, 23 In platelets from healthy subjects, Ca 2ϩ -induced calpain activation increased the number of platelets that adhered to fibronectin in a calpeptin-sensitive manner ( Figure 5C ). Similar responses were observed in platelets from -cal fl/fl but not from PF4--cal Ϫ/Ϫ mice ( Figure 5D ), suggesting a role for -calpain in platelet adhesion. Moreover, in platelets from healthy subjects, extracellular Ca 2ϩ promoted lamellipodia formation and platelet spreading on fibronectin. The latter response was reduced in the presence of calpeptin in platelets from -cal fl/fl and PF4--cal Ϫ/Ϫ mice ( Figure 5E ). Therefore, m-calpain rather than -calpain seems to be activated during platelet spreading.
Calpain inhibition reverses diabetes-associated platelet hyperactivation
Our next step was to determine the effects of calpain inhibition on platelet function. In platelets from healthy subjects, the calpain inhibitors calpeptin and A-705253 24 had moderate inhibitory effects on the thrombin-induced mobilization of Ca 2ϩ and no significant effect on subsequent aggregation, but did attenuate clot retraction (supplemental Figure 3A -C). Both compounds prevented the Ca 2ϩ -induced cleavage of CD31, but the mechanisms of action were distinct: whereas calpeptin prevented the autolytic cleavage of -calpain, A705253 did not (supplemental Figure 3D) .
Given that calpain is activated by redox stress and calpain inhibition had little effect on agonist-induced responses, we hypothesized that calpain treatment may preserve platelet function in a mouse model of diabetes. As with platelets from patients with type 2 diabetes, diabetes in wild-type mice (12 weeks after streptozotocin treatment) resulted in the activation of -and m-calpain and a reduction in levels of septin-5, ILK, FAK, and PYK2. Treating animals over 12 days with A-705253 (30 mg/kg/d orally) had no effect on blood glucose or bleeding times (supplemental Figure 4 ), but was sufficient to increase levels of latent -and m-calpain and increase the levels of their substrates to those observed in nondiabetic mice ( Figure 6A ).
As with the human subjects, diabetes increased levels of CCL5 detected in circulating murine microparticles ( Figure 6B ), and this response was reversed in animals treated with A-705253. CCL5 was also deposited onto endothelial cells in the carotid arteries of diabetic mice, a phenomenon reduced by the calpain inhibitor (supplemental Figure 5) .
Diabetes also accelerated thrombus formation after FeCl 3 -induced carotid artery injury (the time to reach maximum size was CALPAIN ACTIVATION AND THE DIABETIC PLATELET PROTEOME 419 BLOOD, 12 JULY 2012 ⅐ VOLUME 120, NUMBER 2
For personal use only. at King's College London on July 30, 2012. bloodjournal.hematologylibrary.org From 17.5 Ϯ 1.2 minutes in healthy versus 7.5 Ϯ 0.4 minutes in diabetic mice, n ϭ 8 per group, P Ͻ .001; Figure 6C ), potentiated the formation of leukocyte-platelet aggregates in vivo ( Figure 6D ), and enhanced thrombin-induced platelet aggregation in vitro ( Figure  6E ). Whereas thrombus formation in vivo in nondiabetic mice was unaffected by calpain inhibition, A-705253 reduced the maximum thrombus size and decelerated thrombus formation (time to maximum was increased from 7.5 Ϯ 0.4 [n ϭ 8] to 14.7 Ϯ 2.4 minutes in the A-705253-treated diabetic mice [n ϭ 7]; P Ͻ .05; Figure  6C ), reversed the diabetes-induced formation of leukocyte-platelet aggregates in vivo ( Figure 6D ), and attenuated thrombin-induced platelet aggregation ( Figure 6E ).
Discussion
The results of the present study identified septin-5 and the ILK as novel calpain substrates in diabetic platelets and linked the proteolysis of these proteins to the increased secretion and modification of the ␣-granule protein CCL5 and to altered platelet adhesion and spreading. Moreover, it was possible to reproduce the findings using human platelets in a mouse model of diabetes and to prevent the in vivo proteolysis of the substrates identified using a calpain inhibitor. Calpain inhibition was also shown to reverse the hyperreactivity observed in diabetic platelets and the formation of platelet-leukocyte aggregates.
Over the past 10 years, it has become clear that platelets are not simply involved in aggregation and clot formation, but that they also play an active role in vascular homoeostasis, largely by delivering an impressive array of vasoactive substances. Little is known about the changes in platelets that lead to the enhanced deposition of chemokines such as stromal cell-derived factor-1, 25 PF4, or CCL5 26 on the endothelial surface, which in turn promote the recruitment of circulating cells and can thus potentiate vascular disease development. Our data suggest that one of the major changes precipitating these effects is the activation of calpain. However, studying the relevance of these proteases in a human population is hampered by the fact that specific inhibitors are not available for human studies. Therefore, in the present study, we made use of a previously observed phenomenon: that PPAR␥ agonist therapy attenuates platelet Ca 2ϩ levels and calpain activity. 12 Our approach also meant that any positively regulated proteins could either be calpain substrates or proteins directly regulated by PPAR␥. Interestingly, although we did detect one such protein (GPD2), a high percentage of the proteins sampled from the gels were previously characterized calpain substrates.
The first novel calpain substrate identified was septin-5 (also known as CDCrel-1 or PNUT-like), a SNARE-interacting protein previously identified as a Parkin substrate and implicated in the regulation of dopaminergic neurons. 27,28 Interestingly, a neuron defect has been difficult to document in septin-5 Ϫ/Ϫ mice, but platelets lacking the protein demonstrate enhanced aggregation and release stored granule products in response to stimuli that are under the threshold for normal platelets. 15 Septin-5 has been localized to membrane areas surrounding platelet ␣-granules and binds syntaxin 4 to prevent rather than promote secretion. 29 To date, it has been presumed that the phosphorylation of septin-5 in response to platelet agonists dissolves its association with syntaxin to promote granule product release 29 ; however, our data suggest that this can also be achieved by the limited proteolysis of the protein by calpain. This implies that the loss of septin-5 function would result in enhanced secretion of platelet ␣-granule contents in the absence of overt platelet activation, which is exactly what was observed after calpain activation. More recently, different subpopulations of (E) Effect of calpain inhibition on numbers of activated and spread platelets after stimulation of washed platelets from -cal fl/fl and PF4--Cal Ϫ/Ϫ mice with Ca 2ϩ in the absence or in the presence of calpeptin (Cpt). The graphs summarize data obtained in platelets from 4-5 subjects or 6-9 animals per group. *P Ͻ .05; **P Ͻ .01 versus control; #P Ͻ .05 versus Ca 2ϩ -stimulated platelets without calpeptin.
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In the present study, we focused on CCL5 as a marker of ␣-granule release, largely because of its described role in promoting the development of atherosclerosis. 16, 26 We found that calpain activation promoted the release of CCL5 and that the protein itself is a calpain substrate. The finding that -calpain was also secreted from thrombin-stimulated platelets, although initially unexpected, was consistent with our own finding that plasma calpain activity is much higher in samples from diabetic patients than from healthy subjects. It also fits well with a recent report that identified calpain in the platelet secretome. 17 We also observed that the in vitro incubation of CCL5 with calpain resulted in the modification of CCL5 and the generation of a truncated variant (CCL5 3-21) that was more chemotactic for monocytes than the full-length protein.
More than 19 variants of CCL5 are known to exist, 32 and proteases such as dipeptidyl peptidase IV and cathepsin G can generate 3-68 and 4-68 variants of CCL5. 33, 34 Although the clinical significance of these variants is unclear, higher plasma levels of CCL5 (3-68) have been reported in patients with type 2 diabetes. 32 However, the latter peptide was reported to show reduced rather than enhanced activity toward cells expressing the recombinant CCR5 receptor. 33 This was not unexpected, because the N-terminus of many chemokines plays a critical role in the recognition and functional activation of cognate receptors. Given that the variant generated by calpain (3-21) enhanced monocyte adherence, it seems that calpain-mediated modifications of the C-terminus of CCL5 may more than compensate for the lower activity resulting from N-terminal truncation. It is unclear at the moment whether other platelet-derived products may be modified by extracellular calpain, but not all chemokines are calpain substrates, because MCP-1 could not be cleaved by calpain in an in vitro assay.
The second novel calpain substrate we focused on was ILK, which was first identified using a yeast 2-hybrid screen for ␤1-integrin-binding partners. 35 ILK is part of the focal adhesion complex together with PINCH and Parvin, 18 but even though kinase activity has been shown consistently with a recombinant protein, 20,35 whether it acts as a kinase in vivo has proven controversial. [36] [37] [38] Despite the controversy, a dual role for ILK in regulating integrin function and ␣-granule secretion can be extrapolated from studies in platelets from ILK-deficient mice. The latter demonstrate reduced aggregation, fibrinogen binding, and arterial thrombus formation, as well as a selective defect in ␣-granule but not dense-granule secretion. 39 This phenotype fits well with that of the diabetic platelet. In addition, the results of the present study indicate that ILK is inactive when associated with PINCH and that -calpain initiates their dissociation and the subsequent phosphorylation of the ILK downstream target, Akt. A similar mechanism of action was recently proposed in a study looking at heart failure in CALPAIN ACTIVATION AND THE DIABETIC PLATELET PROTEOME 421 BLOOD, 12 JULY 2012 ⅐ VOLUME 120, NUMBER 2
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induced by the down-regulation of PINCH, which led to instability of ILK and the loss of Akt activity. 40 Whereas our data suggest that -calpain is required for the activation of ILK, it seems that the activation of m-calpain results in the degradation of the kinase and prevents Akt phosphorylation.
Given the role of the IPP complex in the regulation of integrin signaling and the fact that the proteolysis of focal adhesion proteins such as talin, paxillin, FAK, and PYK2 is known to regulate focal adhesion dynamics and cell migration, 22,23 it was logical to look at the consequences of calpain activation on platelet adhesion and spreading. We found that -calpain activation, which was also required for the activation of ILK, seems to regulate platelet adhesion (at least on fibronectin), whereas m-rather than -calpain regulates platelet spreading. The latter could be concluded only by comparing responses in platelets from -cal fl/lfl and PF4--cal Ϫ/Ϫ mice, because none of the currently available calpain inhibitors can differentiate between the -and m-calpain isoforms. Although the full spectrum of platelet kinases targeted by calpains remains to be elucidated, our data suggest that in vitro calpain activation and that associated with the development of diabetes must be linked with major changes in different intracellular signaling cascades. Indeed, ILK, PYK2, and FAK levels were almost undetectable in platelets from healthy subjects or mice after calpain activation in vitro or in diabetic platelets. However, normal levels of the kinases were observed in platelets from patients treated with a PPAR␥ agonist and diabetic animals treated with a calpain inhibitor.
It is well accepted that platelets contribute actively to the diabetes-associated accelerated development of atherothrombosis and enhanced platelet reactivity may account for the refractory response of diabetic patients to conventional antiplatelet therapy. The findings that calpain activity is elevated in platelets from diabetic subjects and that a calpain inhibitor reversed the diabetesinduced hyperactivation of platelets in mice suggest that Ca 2ϩ -activated proteases may be a promising therapeutic target for a better management of diabetes-associated platelet and vascular complications. Calpain inhibition may also underlie platelet activation in other conditions, because many of the proteins identified as calpain substrates in diabetic humans and mice (including ILK) were also reported to be altered in platelets from patients with acute coronary syndromes. 41, 42 Although in the present study, we found no significant effects on platelet number or function in otherwise healthy mice after 12 days of treatment, other studies indicate that the long-term treatment with A-705253 is well tolerated and can protect against retinal damage 43 and penile nitrergic nerve and dysfunction in diabetic mice. 44 Other calpain inhibitors attenuate angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in LDL receptordeficient mice 45 and angiotensin II-induced endothelial dysfunction in rats and mice. 46 The results of the present study, together with the studies showing a beneficial effect of calpain inhibition in vascular disease, highlight the potential of calpain inhibition for the treatment of the vascular complications of type 2 diabetes. However, future efforts should focus on the development of compounds devoid of the problems of calpain isoform selectivity and specificity versus other proteases, 47 
CALPAIN INHIBITION STABILIZES THE PLATELET PROTEOME AND REACTIVITY IN
DIABETES
Supplementary materials and methods
Reagents
Cell culture media were purchased from Gibco (Invitrogen; Darmstadt, Germany). Calpeptin was from Calbiochem (Darmstadt, Germany), type I Collagen and fibronectin were from BD transduction laboratories (Heidelberg, Germany). Thrombin was from Hemochrom Diagnostica (Essen, Germany), The calpain inhibitor N-(1-benzyl-2-carbamoyl-2-oxoethyl)-2-[E-2-(4-diethyl-aminomethylphenyl)ethen-1-yl]benzamide (A-705253) was provided by Abbott GmbH & Co KG (Ludwigshafen, Germany). The anti-Akt and anti-Ser734-Akt antibodies were from Cell Signaling (New England Biolabs, Frankfurt, Germany), the anti-FAK, the anti-α-parvin, anti-septin-5, anti-ILK and the anti-syntaxin-4 antibodies were from Abcam (Cambridge, UK), the anti-CCL5 was from Molecular Probes (Invitrogen; Darmstadt, Germany), the anti-PINCH and anti-PYK2 antibodies were from BD transduction laboratories (Heidelberg, Germany); anti-PECAM1 was from Dako (Glostrup, Denmark). All other compounds were from Sigma-Aldrich (Steinheim, Germany).
Pioglitazone study population
A total of 13 patients (5 women, 8 men; mean age, 47±5.4 years; age range, 30 to 70 years) with type 2 diabetes mellitus were used in this study. Patients were treated with either pioglitazone 30 mg/day (Actos®, Takeda; Aachen, Germany) or placebo each for 12 weeks in a cross sectional design. There was a 4 week washout period between the different treatments. The study protocol was approved by the ethics committee of the Technical University of Dresden (No. EK 233112006), and all of the participants gave written informed consent. Nondiabetic, age-matched subjects (7 women, 8 men; mean age, 40.25±6.5 years; age range, 23 to 50 years; HbA 1c , 5.2±0.6%; fasting plasma glucose, 5.1±0.2 mmol/L) who had not taken any medication known to interfere with platelet aggregation for at least 10 days before the experiment served as the control group.
Diabetic population
A total of 30 patients (16 women, 14 men; mean age, 47±5.4 years; age range, 30 to 70 years) with type 2 diabetes mellitus attending the clinic for routine control visits were included in the study. Hemoglobin (Hb) A 1c ,over 7.4% and fasting plasma glucose, 8.2±0.7 mmol/L. All patients were treated with insulin alone or in combination with metformin. Nondiabetic, agematched subjects (12 women, 18 men; mean age, 42.4±4.5 years; age range, 25 to 65 years; HbA 1c , 5.2±0.6%; fasting plasma glucose, 5.1±0.2 mmol/L) who had not taken any medication known to interfere with platelet aggregation for at least 10 days before the experiment served as the control group. The study protocol was approved by the ethics committee of the Goethe University Hospital (No. E 61/09 geschäfts Nr 86/09) and all of the participants gave written informed consent.
Proteomic analysis
Platelet extracts were prepared using a lysis buffer (8M urea, 4% w/v CHAPS, 30mM Tris-Cl, pH 8.5) compatible with DIGE labeling (GE healthcare). After centrifugation at 13,000g for 10 minutes, the supernatant containing soluble proteins was harvested and the protein concentration was determined using a modification of the method described by Bradford. The fluorescence dye labeling reaction was carried out at a dye/protein ratio of 200pmol/50µg. After incubation on ice for 30 minutes, the labelling reaction was stopped by scavenging nonbound dyes with 10mM lysine (L8662, Sigma) for 15 minutes. For two-dimensional gel electrophoresis, samples were mixed with 2x buffer (8M urea, 4% w/v CHAPS, 2% w/v DTT, 2% v/v Pharmalytes 3-10 for IEF), 50µg per sample were diluted in rehydration solution (8M urea, 0.5% w/v CHAPS, 0.2% w/v DTT, and 0.2% v/v Pharmalyte pH 3-10) and loaded on IPG strips (18cm, pH 3-10, nonlinear, GE healthcare). After rehydration overnight, strips were focused at 0.05 mA/IPG strip for 28 kVh at 20°C (IPGphor, GE healthcare). Once IEF was complete the strips were equilibrated in 6M urea containing 30% v/v glycerol, 2% w/v SDS and 0.01% w/v Bromophenol blue, with addition of 1% w/v DTT for 15 minutes, followed by the same buffer without DTT, but with the addition of 4.8% w/v iodoacetamide for 15 minutes. SDS-PAGE was performed using 12% T (total acrylamide concentration), 2.6% C (degree of cross-linking) polyacrylamide gels without a stacking gel, using the Ettan DALT system (GE healthcare). The second dimension was terminated when the Bromophenol blue dye front had migrated off the lower end to the gels. After electrophoresis, fluorescence images were acquired using the Ettan DIGE imager (GE healthcare). Finally, gels were fixed overnight in methanol: acetic acid: water solution (4:1:5 v/v/v). Protein profiles were visualized by silver staining using the Plus one silver staining kit (GE healthcare), with slight modifications, 1 to ensure compatibility with subsequent mass spectrometry analysis. For documentation, silver-stained gels were scanned in transmission scan mode using a calibrated scanner (GS-800, Bio-Rad). DIGE gels were analyzed using the Decyder software (Version 7.0, GE healthcare). All 2-DE gels were of high quality in terms of resolution as well as consistency in spot patterns. Spots exhibiting a statistical difference (fold change >1.2, p<0.05) were excised for identification. A detailed methodology is available at http://www.vascular-proteomics.com.
Tandem Mass Spectrometry
In-gel digestion with trypsin was performed according to published methods 2 modified for use with an Investigator ProGest (Genomic Solutions) robotic digestion system. Following enzymatic degradation, samples were separated by liquid chromatography on a reversephase column (C18 PepMap100, 3 μm, 100Å, 25 cm, Dionex) and applied to a LTQ Orbitrap XL mass spectrometer (Thermo Scientific). Spectra were collected from the mass analyzer using full ion scan mode over the m/z range 450-1600. Six dependent MS/MS scans were performed on each ion using dynamic exclusion. Database searches were performed using the TurboSEQUEST software (Bioworks Browser version 3.3.1, Thermo Fisher) against human database (20333 protein entries, UniProt KB Release 14.6, 16-Dec-2008) and the following filters were applied (Scaffold software, version 2.6, Proteome Software): peptide probability > 95%, protein probability >99.9%, minimum no. of peptides per protein >=2.
Calpain cleavage of CCL5 (RANTES)
Recombinant CCL5 (Sigma-Aldrich) was incubated with recombinant calpain (Sigma-Aldrich; 1U, 30°C, 30 minutes). Calpain was activated by adding cysteine (5 mmol/L) and Ca 2+ (5 mmol/L) to the reaction buffer.
MS analysis of CCL5
CCL5 and calpain-treated CCL5 samples were separated by SDS-PAGE and the corresponding area cut into slices. After reduction and carbamidomethylation gel pieces were digested overnight with MS grade trypsin (Promega), the extracted peptides were then lyophilized and resuspended in 5% acetonitrile/0.5% formic acid. The MS analysis of tryptic digested proteins was performed by nano-LC-MS/MS and CID fragmentation on an LTQOrbitrap mass spectrometer. Mass spectra were analyzed by Mascot Server 2.2 by matching them against the Homo sapiens Uniprot protein database. The following Mascot search parameters were used: maximum of one missed cleavage, cysteine carbamidomethylation, methionine oxidation and mass tolerance for MS scans of 8 ppm and 0.8 Da for MS/MS, respectively. The Mascot searches were performed in a first round using the error-tolerant search option and after the cleavage sites in CCL5 had been identified, the sequences of CCL5 in the database were shortened according to the identified cleavage site and Mascot searches repeated without the error-tolerant search option. Only peptides with individual ions scores indicating identity or extensive homology; (P<0.05) were taken into account.
Animals
C57BL/6 mice (6-8 weeks old) were from Charles River (Sulzfeld, Germany). Floxed µ-calpain -/-mice were generated by TaconicArtemis GmbH (Cologne, Germany) and bred with animals expressing the Cre-deleter under the control of the PF4 promoter (The Jackson Laboratory, Bar Harbor, Maine, USA) to generate mice lacking µ-calpain in platelets.
Briefly, mice were generated using C57BL/6 embryonic stem cells for gene targeting. Positive selection cassettes flanked by FRT/F3 sites were deleted by crossing with a ubiquitously expressing FLP1 recombinase strain (Figure I) . Excision after Cre recombination was confirmed by PCR with primers to detect a floxed portion of the construct 5'-TCT ACG TAC AGG GTT CCA AGC-3', 5'-CCA CGA GAG GGT GT TAG ACC-3' with 213 bp product lengths for the wild-type alleles, 397 bp for the conditional alleles (loxP and F3) and by PCR with primers to detect the portion of the targeting construct that remains in the genome: 5'-GCT TAG AGG CTA ACA GCT AGA CC-3' and 5'-GGT CTAA CAC CCT CTC GTG G-3' (300 bp), product specificity were demonstrated by HindIII digestion resulting in a 181 and 119 bp fragment. Genomic DNA from tail samples were used for the PCR genotyping with the following parameters: 95°C for 5 minutes, followed by 35 cycles, at 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds and 72°C for 10 minutes. For PF4-cre detection the primers used were: 5´-CCC ATA CAG CAC ACC TTT TG-3´ and 5´-TGC ACA GTC AGC AGG TT-3´ with the following parameters: 94°C for 5 minutes, followed by 30 cycles, at 95°C for 30 seconds, 60°C for 30 seconds, 72°C for 30 seconds and 72°C for 2 minutes. Gt(ROSA)26Sor tm16(Cre)Arte (TaconicArtemis) was detected with the following primers 5´-ACG ACC AAG TGA CAG CAA TG and CTC GAC CAG TTT AGT TAC CC. 
Diabetes induction
Diabetes was induced with a single intraperitoneal injection of streptozotocin (150 mg/kg) and animals were considered diabetic when fasting plasma glucose was over 250 mg/dl. In 4 some experiments animals were treated by oral gavage with the calpain inhibitor A-705253 (30 mg/kg/day) for 12 days after 12 weeks untreated diabetes.
Platelet isolation
Human platelets: Platelets were obtained by centrifugation (900g, 7 minutes) of platelet-rich plasma, as described. 3 The resulting pellet was washed in Ca
2+
-free HEPES buffer (mmol/L: NaCl, 136; KCl, 2.6; MgCl 2 , 0.93; NaH 2 PO 4 , 3.26; glucose, 5.5; HEPES, 3.7; pH 7.4 at 37°C). Platelet pellets were snap frozen with liquid nitrogen and stored at -80°C until use for Western blot or resuspended in HEPES buffer to a density of 4x10 8 platelets/mL for the measurement of intracellular Ca 2+ or platelet aggregation as described. 4 Murine platelets: Mice were anesthetized with isoflurane and blood was collected via cardiac puncture into a syringe containing 10% acidic citrate dextrose (120 mmol/L sodium citrate, 110 mmol/L glucose, 80 mmol/L citric acid) as anticoagulant. Platelets were prepared from whole blood by differential centrifugation and resuspended in Ca ] i was determined by measuring changes in fura-2 fluorescence as described. 4 In vitro calpain substrate determination µ-Calpain was activated by incubation of washed platelets with 5 mmol/L CaCl 2 for 30 minutes as described 5 and m-calpain was activated by CaCl 2 (5 mmol/L) and ionomycin (1 µmol/l).
Calpain activity assay
Calpain activity was assessed by monitoring the formation of the fluorescent metabolite 7-amino-4-methylcoumarin (AMC) from N-succinyl-Leu-Leu-Val-Tyr7-amido-4-methylcoumarin.
ILK activity assay
ILK was co-immunoprecipitated with PINCH from Triton X-100-soluble platelet lysate. The immunoprecipitate was treated with solvent, µ-calpain or m-calpain (1U/mL for 30 minutes at 30°C) in order to induce ILK cleavage. The complex was then added to platelet lysates (obtained after 3 cycles of freezing and thawing) as a source of Akt. Reactions were stopped after 10 minutes by adding SDS sample buffer.
Immunoblotting
Washed human or murine platelets were solubilized in Triton X-100 lysis buffer and Triton X-100 soluble proteins were separated by SDS-PAGE and subjected to Western blotting and visualized by enhanced chemiluminescence using a commercially available kit (Amersham, Freiburg, Germany), as described. 
Platelet-derived microparticles
Microparticles were isolated by centrifugation of platelet poor plasma (40000g, 4°C, 45 minutes). After washing, microparticles were resuspended in platelet HEPES buffer and labeled with either a FITC-conjugated anti-human CD61 antibody (BD Pharmingen) or a FITC-conjugated IgG1κ isotype control (BD Pharmingen). The suspension was washed, resuspended in PBS and analyzed in a FACScan flow cytometer using a CellQuest software (Becton Dickinson, CA). Human platelet-derived microparticles were 62.8±7.9% of total circulating microparticles in healthy individuals.
Platelet aggregation
Aggregation of washed human or murine platelets (4x10 8 platelets/mL) was measured as described 4 using an 8-channel aggregometer (PAP8, Mölab, Germany).
Clot retraction
Platelet-rich plasma (adjusted to 300x10 9 platelets/mL for human platelets and 5x10 8 platelets/mL for murine platelets, 300 µL) obtained by centrifugation of whole blood at 250g for 10 minutes, was stimulated with thrombin (0.3 U/mL for human and 1U/mL for murine) in the presence of CaCl 2 (20 mmol/L) and 10 µL erythrocytes to enhance the contrast of the clot. The clots were allowed to retract for up to 3 hours at 37°C and were photographed at different time points. The extent of retraction was quantified using TINA20 software (Raytest GmbH, Straubenhardt, Germany).
Thrombus formation in a FeCl 3 -induced carotid artery model
To assess thrombus formation in vivo, mice were anesthetized by intraperitoneal injection of ketamine and xylazine and placed on a heated mat. The fluorescent dye 3,3'-dihexyloxacarbocyanine iodide (DIOC 6 ; Ivitrogen, Darmstadt, Germany) was injected into the jugular vein (5 µL of a 100 µmol/L solution/g body weight) to allow visualization of the thrombus. Thereafter, a segment of the right carotid artery was exposed and injury was induced by the topical application of FeCl 3 for 2 minutes (Whatmann paper 1 mm 2 soaked with 0.2 µL of 10% FeCl 3 ) as described. 4 The artery was then rinsed with saline and thrombus formation was monitored for 30 minutes by placing the carotid artery under a fluorescence microscope equipped with a camera (AxioScope, Carl Zeiss, Jena, Germany). Fluorescent images were acquired sequentially (1 image/second) and thrombus size was quantified using AxioVision 4.7 imaging software (Carl Zeiss).
Platelet adhesion and spreading assays
Static adhesion assays were performed as described. 7 Washed human or murine platelets were stimulated or not with 5 mmol/L CaCl 2 in the absence or in the presence of the calpain inhibitor calpeptin. Platelet suspensions (5x10 4 platelets/µL) were seeded on glass slides (µ-Slide 8 well, ibidi, Martinsried, Germany), coated with fibronectin (100 µg/mL) and incubated at 37°C for 15 minutes for human platelets and 60 minutes for murine platelets. Non adherent platelets were washed out and adherent and spread platelets were fixed. Images were captured by a AxioCam MRm on a Cell Observer microscope (Zeiss, Jena, Germany) and analyzed using the imaging software AxioVision 4.8 (Zeiss, Jena, Germany).
Platelet-derived products
Washed human platelets were stimulated or not with CaCl 2 (5 mmol/L) for 30 minutes and then centrifuged (800g, 5 minutes, 37°C). Platelets were resuspended in HEPES buffer and stimulated with thrombin (1U/mL) for 10 minutes at 37°C. The platelet suspension was again centrifuged (800g, 5 minutes, 37°C) and the supernatant was collected and directly placed on ice. Supernatant was ultracentrifuged (50.000g/1h/4°C) in order to remove contaminating microparticle and was either placed on ice for further analysis or stored at -80°C until further use. Transforming growth factor (TGF)- and CCL5 in the releasate were quantified using commercially available ELISAs (R&D systems, Wiesbaden, Germany) according to the manufacturer's instructions. The serotonin ELISA was from IBL (Hamburg, Germany).
Cell culture
Human umbilical vein endothelial cells were isolated and cultured as described. 8 To assess proliferation, non-confluent cells (passage P1) were stimulated with either vascular endothelial cell growth factor (VEGF; 60ng/mL) or platelet derived products (1:1 dilution with MCDB medium) and maintained in culture. Cells were counted after 48, 72 and 96 hours using the Casy cell counter (Roche, Mannheim, Germany) THP-1 monocytic cells (ATCC, Wesel, Germany) were cultured in RPMI 1640 containing 100 units/mL penicillin, 100 µg/mL streptomycin and 10% heat inactivated fetal calf serum. THP-1 cell migration was assessed using a modified Transwell chamber system with membrane inserts (8-µm pore size; BD Biosciences, Heidelberg, Germany). Cells were seeded at a density of 100,000 cells/cm 2 in the Transwell inserts and monocyte migration was evaluated by counting the number of cells in the lower wells after 2 hours. Cell migration was assessed in response to fresh culture medium alone, recombinant CCL5, µ-calpain or the µ-calpain-cleaved CCL5.
Immunofluorescence. CCL5 immobilized on the surface of endothelial cells was detected as described. 9 After preincubation with solvent or calpeptin (10 µmol/L, 30 minutes), platelets 6 were stimulated or not with CaCl 2 (5mmol/L, 30 minutes), centrifuged and resuspended in platelet buffer. Platelets were added to endothelial cells under continual shaking (50 rpm, 37°C). After 1 hour the endothelial cells were washed, fixed with 4% paraformaldehyde and blocked with 2% BSA. Samples were then incubated with antibodies against β3-integrin to identify platelets, and anti-CCL5 antibody (VL-1) or its isotype control and corresponding Alexa fluorescent secondary antibodies.
En face staining
Carotid arteries were carefully cleaned of fat and connective tissue. Arteries were opened and labeled in situ with anti-CCL5 antibody (R&D Systems, Wiesbaden, Germany), or IgG control coupled to Protein G green fluorescent beads (Spherotech, 1 µm) for 1 hour at 37°C. After washing and fixation with paraformaldehyde (4% v/v in PBS) carotid arteries were mounted on glass slides with fluorescent mounting medium (Dako, Eching, Germany). En face images were obtained using a Zeiss LSM-510 meta laser confocal microscope.
Flow cytometry analysis of platelet-leukocyte aggregates
Whole murine blood (100 µL) was incubated with 1 mL erythrocyte lysis buffer to lyse erythrocytes (30 minutes, room temperature). After centrifugation and washing pellets were fixed with formalin (2% vol/vol in PBS) then washed and resuspended in platelet buffer. 
